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Abstract 
Cardiac Troponin I (cTnI) levels are considered an important diagnostic tool in acute coronary events. However, 
there is controversy over their sensitivity, specificity and prognostic value in haemodialysis (HD) patients. The aim 
of this study was to explore the behaviour and prognostic value of cardiac troponin I in HD patients. Thirty-four 
asymptomatic patients undergoing long-term haemodialysis were studied. Samples of blood were collected at 
the start of the study (pre- and post-dialysis serum), after three years (pre-dialysis serum and plasma, with and 
without the addition of heterophilic-antibody-blocking reagent (HBR) and after five years (pre-dialysis serum). 
Quantitative cardiac troponin I was measured with an AxSYM cTnI micro-particle enzyme immuno-assay and 
qualitative cTnI with a Hexagon Troponin immuno-chromatographic one-step test.
It did not prove possible to detect any significant association between pre- and post-dialysis cTnI levels. 
Comparison of results for serum and heparin plasma revealed no statistically significant difference between 
the level of cTnI and the mean values for plasma and serum with and without the addition of HBR. The cTnI 
concentrations in the samples without added HBR were lower than in those with HBR, but no statistically 
significant difference between the mean for cTnI and the mean of samples with and without added HBR was 
observed. During the study, 35.2% of the population died. A positive association was observed between the 
cTnI values in the patients still living and those patients who died from ischaemic cardiomyopathy (p = 0.039). 
The crude risk of death by cardiovascular disease was increased eight-fold (the 95% confidence interval being 
1.2 to 51.1) in patients with a cTnI concentration greater than 0.04 ng/mL. Levels of cTnI may reflect occult 
myocardial ischemia and identify haemodialysis patients who face a greater risk of death.
Keywords: cardiac biomarkers, cardiac troponin I, chronic renal failure, haemodialysis mortality, myocardial 
injury, prognostic value of cardiac troponin I. 
Resumen
comportamiento y valor pronóstico de la troponina i cardiaca en suero en pacientes con 
enfermedad renal final sometidos a hemodiálisis de largo plazo. Analisis de resultados 
quinquenales
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Los niveles troponina I cardiaca (cTnI) se consideran una importante herramienta de diagnóstico en los eventos 
coronarios agudos. Sin embargo, hay controversia sobre su sensibilidad, especificidad y valor pronóstico en 
la hemodiálisis (HD) de los pacientes. El objetivo de este estudio fue explorar el comportamiento y el valor 
pronóstico de la troponina I cardiaca en pacientes en HD. Se estudiaron treintaicuatro pacientes asintomáticos 
sometidos a hemodiálisis a largo plazo. Las muestras de sangre fueron tomadas al inicio del estudio (pre-y 
post-diálisis en suero), después de tres años (pre-diálisis en suero y plasma, con y sin la adición de anticuerpos 
heterófilos reactivos de bloqueo (HBR) y después de cinco años (suero pre-diálisis). Se midió la troponina 
I cardiaca cuantitativa con micro-partículas AxSYM cTnI de la enzima inmuno-ensayo de cTnI y la cualitativa 
con una prueba de un solo paso de inmuno Troponina Hexagon-cromatografía.
No fue posible detectar ninguna asociación significativa entre los niveles de cTnI pre-y post-diálisis. La 
comparación de los resultados de la heparina de suero y plasma no reveló ninguna diferencia estadísticamente 
significativa entre el nivel de cTnI y los valores promedio para el plasma y suero con y sin la adición de HBR. 
Las concentraciones cTnI en las muestras sin HBR añadido fueron más bajas que en aquellas con HBR, pero 
no se observó diferencia estadísticamente significativa entre la media de cTnI y la media de las muestras 
con y sin adición de HBR. Durante el estudio, el 35,2% de la población murió. Se observó una asociación 
positiva entre los valores de cTnI en los pacientes que aún viven y en los pacientes que murieron a causa 
de la miocardiopatía isquémica (p = 0,039). El crudo riesgo de muerte por enfermedad cardiovascular se 
ha multiplicado por ocho (el intervalo de 95% de confianza estando entre 1,2 y 51,1) en pacientes con una 
concentración de cTnI superior a 0,04 ng/ml. Los niveles de cTnI pueden reflejar la isquemia miocárdica oculta 
e identificar los pacientes en hemodiálisis que se enfrentan a un mayor riesgo de muerte.
Palabras clave: biomarcadores cardíacos, insuficiencia renal crónica, lesión miocárdica, troponina I cardiaca, 
mortalidad de hemodiálisis, valor pronóstico de la troponina I cardiaca
Introduction
Cardiac disease is the leading cause of morbidity and 
mortality in patients with end-stage renal disease (ESRD). 
The prevalence of ischaemic heart disease (IHD) in 
haemodialysis patients is 10 to 20 times greater than in 
the general population, 50% of their mortality being due 
to cardiovascular disease (1). Patients with chronic renal 
failure (CRF) are at greater risk of silent ischaemia and 
atypical clinical presentation during an acute coronary 
syndrome. Angina is often absent in patients who suffer 
from both ESRD and coronary artery disease, occurring 
in only 17% of cases (2). 
Earlier detection of cardiovascular abnormalities in 
these patients might allow earlier interventions to reduce 
morbidity and mortality. However, in patients receiving 
maintenance dialysis, the clinical symptoms of cardiac 
damage are difficult to diagnose and may be misleading. In 
addition, the traditional cardiac markers, such as creatine 
kinase (CK), creatine kinase muscle-brain fraction (CK-
MB) and myoglobin, have been found to be deceptively 
high in patients using dialysis (1-3).
For this reason, some recent research has monitored 
cardiac biomarkers such as cardiac troponins and brain-
type natriuretic peptides (BNPs), in addition to clinical 
information such as diabetes and hypertension. The 
purpose was to assist in identifying ESRD patients with 
coronary artery disease who face a high risk of death (1,4). 
Furthermore, inflammation is known to play an essential 
role in the pathogenesis of coronary heart disease. Several 
studies have demonstrated that increased markers of 
inflammatory activity, like C-reactive protein (hs-CRP), 
pentraxin 3, pro-inflammatory cytokines and 8-oxo-7,8-
dihydro-2'deoxyguanosine, are associated with increased 
risk of death in healthy individuals, in patients with acute 
coronary syndrome, and in patients with impaired renal 
function (5,6). Some of these new biomarkers, such as 
the BNPs and hs-CRP, have been shown to be prognostic 
indicators of survival in patients with congestive heart 
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failure (4). However, there is controversy in the literature 
regarding the sensitivity, specificity and prognostic value 
of troponins, particularly cardiac troponin I (cTnI).
Nonspecific raised cTnI has been reported in kidney 
patients in the absence of any clinical suspicion of acute 
myocardial ischaemia, possibly due to variable expression 
in extracardiac tissue as a consequence of the uraemic 
environment or to analytical interference from many 
nonspecific causes affecting almost all cTnI immuno-
assays, producing false positive or negative results (6,7). 
Furthermore, although recent studies demonstrate that 
serum or plasma cTnI is an important predictor of long-
term, all-cause mortality and cardiovascular mortality in 
patients with ESRD, and that high concentrations of cTnI 
are associated with increased risk of coronary artery disease 
in this population (1-3), other studies conclude that cTnI 
has little predictive value in renal insufficiency and they do 
not identify it as an independent risk factor (8,9). Owing 
to the uncertainty about the usefulness of cTnI in ESRD, 
the aim of present study was to evaluate the behaviour 
and prognostic value of cTnI in a population of chronic 
haemodialysis patients.
Subjects and Methods
Subjects
A total of 34 patients with end-stage renal failure 
undergoing long-term haemodialysis three times per week 
in the haemodialysis unit of the “Clínica San Rafael” 
University Hospital in Bogota, Colombia, were studied 
during the period 1999 to 2004. The patients had no 
history of angina during the previous three months or 
acute myocardial infarction (AMI) during the previous 
year. Exclusion criteria were: recent acute coronary artery 
disease (CAD) defined as occurring in the preceding 
three-month period, chest pain, major cardiovascular 
surgery, habitual consumption of cocaine, presence of 
rheumatoid factor, therapy with tricyclic antidepressives, 
and high concentrations of alkaline phosphatase. 
The study protocol was approved by the institutional 
committee for medical ethics of the “Clínica San Rafael” 
University Hospital and a written declaration of informed 
consent was obtained from each patient enrolled. The 
initial clinical evaluation included a review of medical 
records and hospital information systems. Cardiac status 
was determined by two-dimensional echocardiography. 
The echocardiography was repeated again at the three-year 
point and a further clinical evaluation was undertaken 
after three and five years. All patients were treated with 
conventional bicarbonate haemodialysis using cellulose 
membranes. The duration of each dialysis session was 
four hours.
blood Sampling and Analysis
Blood was collected from the patients during the 
second dialysis session of the week. At the beginning of 
the study, 10 mL of blood was collected before and after 
dialysis and centrifuged within one hour of collection. 
The serum samples were stored at -20oC until analysis. 
The concentrations for cTnI were obtained by means of 
a quantitative method.
Three years later, a sample of serum and of heparin 
plasma was taken in the pre-dialysis session. The blood 
samples were centrifuged within 1 hour of collection and 
stored at -20oC until analysis. Measurement of cTnI was 
carried out with and without added heterophilic-antibody-
blocking reagent (HBR), by means of a quantitative 
method. Five years after the study was initiated, pre-
dialysis serum samples were collected and cTnI was 
measured with a troponin I rapid bedside assay. 
Quantitative cTnI was measured with an AxSYM 
cTnI microparticle enzyme immuno-assay (Abbott 
Laboratories, Colombia). According to the manufacturer, 
cTnI concentrations of 0.04 ng/mL or greater were 
considered high. Qualitative cTnI values were obtained 
with a Hexagon Troponin immuno-chromatographic 
one-step test (Human Gesellschaft, Germany), with 
a sensitivity limit of about 1 ng/mL. The results were 
reported as positive or negative.
Statistical Methods
The level of cTnI was evaluated in continuous and 
categorical form for values equal to or less than 0.04. 
The following variables were categorized in binary (yes 
or no) form for analysis: aetiology of ESRD, associated 
pathology, initial heart disease, new cases of heart disease 
after three years. The respective categories are shown in 
Table 1. The final state of patients was categorized as: 
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still living, died of cardiovascular disease, and died from 
other causes. Analysis of the data was performed with 
the SPSS software package (version 13.0). The normality 
pair assumption was verified for quantitative variables 
(Shapiro-Wilk test). A non-parametric test (Wilcoxon) 
was used to compare cTnI levels. A Spearman’s rank 
correlation was carried out to evaluate the behaviour of 
cTnI with respect to age. The difference of proportions 
was obtained with chi-square test. Statistical significance 
was assumed for values of p less than 0.05. Two-by-two 
frequency tables were drawn up to obtain the ratio of 
disparity with a confidence interval of 95%. The values 
of cTnI in accordance with changes in heart disease were 
evaluated with the Friedman test.
Results
Patients
Clinical characteristics and demographic information 
available for the 34 patients are summarized in Table 1. 
The average age of the population was 50 years, 60% of 
the patients were women, and the average number of 
months on dialysis was 23. With respect to the aetiology 
of chronic renal disease, the pathologies that predominated 
were hypertensive kidney disease and Type 2 diabetes 
mellitus. Hypertensive kidney disease was roughly equally 
spread between men and women, whereas Type 2 diabetes 
was twice as common in women as in men. The initial 
echographic evaluation confirmed that 35.3% of the 
patients had heart disease. The main cardiac pathologies 
table 1. Clinical characteristics of the population studied
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were cardiopathies. The second echocardiography showed 
13 new cases of cardiac disease. In this case also, the largest 
percentage related to cardiopathies.
Outcomes for cardiac troponin i
The cTnI values for the whole population studied are 
given in Table 2. The amounts of cTnI recorded did not 
have a normal distribution in any of the measurements. 
The mean pre-dialysis concentration of cTnI was 0.46 ng/
mL, values ranging between 0.0 and 9.8, and the post-
dialysis average was 0.72 ng/mL, with a range of 0.0 to 
13.3. No significant difference could be detected between 
the median values for the pre- and post-dialysis sessions (p 
= 0.213) at the beginning of the study, Table 2.
table 2. cTnI values for the population studied.
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Those patients for whom figures are not given died 
before the respective measurements were taken.
Comparison of results for serum and heparin plasma 
revealed no statistically significant difference between the 
level of cTnI and the mean values for plasma and serum 
with and without added HBR (p = 0.480 and p = 0.063, 
respectively). Similarly there was no statistically significant 
difference between the first and the second quantitative 
measurements (p = 0.959 and p = 1.000, respectively). 
None of the patients had cTnI concentrations above 
the detection limit in the troponin I rapid bedside assay.
There was no significant correlation between cTnI levels 
and age (p = 0.75) or between cTnI levels and the aetiology 
of chronic renal disease (p = 0.50). However, a statistically 
significant difference was found between cTnI values and 
sex (p = 0.00), cTnI concentrations and the associated 
pathology (p = 0.09), and between shorter times on dialysis 
and undetectable concentrations of cTnI (p = 0.027). Of 
the patients who had spent 1 to 23 months on dialysis, 70% 
had undetectable cTnI concentrations. In contrast, 76.5% 
of the patients who had 24 months or more of treatment 
showed cTnI levels greater than 0.04 ng/mL.
With respect to the echographic evaluations, a 
borderline association was found between pre-dialysis 
cTnI levels and initial cardiac disease (p = 0.052), but not 
between post-dialysis levels and initial cardiac disease (p 
= 0.75). A significant association was observed between 
echographic changes corresponding to new cardiac 
damage and pre-dialysis cTnI concentrations in serum 
samples taken three years into the study (p = 0.00). During 
the five years of the study twelve false negative results 
were recorded, affecting nine patients at the beginning 
of the work and three patients at the three-year point. 
One false positive measurement of cardiac troponin I 
was also detected. 
Predictive Value of ctni Measurements
The clinical characteristics and cTnI levels for those 
patients who died are shown in Table 3. During the study 
35.2% of the population died. Nine patients died during 
the first twelve months of observation and three over the 
course of the following four years. All the patients who 
died had cardiac disease, and in 58.3% of them, the cause 
of death was heart failure. Of the patients who died 75% 
had cTnI concentrations above the upper reference limit of 
0.04 ng/mL. There was a statistically significant difference 
between pre-dialysis and post-dialysis cTnI and death 
from cardiac disease (p = 0.04 and p = 0.048, respectively), 
on which see Figure 1, and between cTnI levels and cardiac 
pathology in the patients who died (p = 0.038). The 
risk of death from cardiovascular disease was eight times 
higher for patients with a cTnI concentration greater than 
0.04 ng/mL, as compared to those with an undetectable 
concentration (the 95% confidence interval being 1.25 to 
51.3; p = 0.017). Consideration of cTnI levels and the vital 
state of the patients demonstrated a significant association 
between survival and cTnI concentrations of 0.0 ng/mL 
(p = 0.037). Of the 22 patients who survived the three 
phases of the study, 72% had undetectable concentrations 
of cTnI in all their evaluations and were still alive in the 
first quarter of 2007, Figure 1, Table 3. 
Discussion
Troponin I is a highly sensitive and specific marker for 
myocardial ischaemia. This specificity has engendered a 
great deal of interest in its value as a marker of subclinical 
ischaemia and as a predictor of death among haemodialysis 
patients. However, the existence of different cTnI assays 
with a wide diversity of cut-off values, the variability in 
pre- and post-dialysis determinations and the presence 
of false positive and negative results combine to create 
confusion and limit the implementation of cTnI as a 
screening test for ESRD patients. The findings presented 
here confirm other studies in several aspects related 
figure 1. Pre-dialysis cTnI and death from cardiovascular 
disease.
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to the specificity, prognostic value and methods for 
quantification of cTnI, and add new data that contribute 
to evaluation of a potential role for this biomarker to aid 
in clinical decisions concerning ESRD patients.
Few studies have compared cTnI concentrations 
before and after dialysis sessions, and their results are 
contradictory. Some of them have shown greater cTnI levels 
after dialysis, others before, yet others have not detected 
significant changes between pre- and post-dialysis values 
(3,9-11). Reasons for this variation might include the type 
of clearance and the membranes used in the dialysis. With 
high-flux membranes, diffusive clearance removes molecules 
up to 15 kDa, whereas with low-flux membranes, only 
molecules up to 5 kDa are removed. Convective clearance 
removes molecules up to a high molecular mass when 
high-flux membranes are used, but only molecules up to 
9 kDa with low-flux membranes (10). This hypothesis 
is sustained by several studies that report increases and 
decreases in post-dialysis levels of cTnI, with the same type 
of membrane used (3). 
Other possible causes are the absorption of TnI isoforms 
by the dialysis membrane and the type of methodology 
employed for measuring cTnI (9,11). A recent study 
compared pre- and post-dialysis cTnI concentrations, 
second and third generation immuno-assays being used. 
Eleven patients had higher pre-dialysis cTnI levels with 
the second immuno-assays, and only one with the third 
generation (11). The findings reported here showed no 
changes between pre- and post-dialysis evaluations using 
a low-flux membrane (cellulose) and a second generation 
immuno-assay. Owing to the variations in the levels of 
cTnI, the authors of this paper concur with other workers 
in the field in recommending pre-dialysis estimations.
table 3. Clinical characteristics and cTnI levels for patients who died. 
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Although for the last decade cTnI has been considered 
the most specific among the currently available biochemical 
markers of myocardial damage, its value in the presence of 
chronic kidney failure has been questioned, mainly because 
of the presence of nonspecific rises in patients, whether 
or not they are being treated with renal substitution 
(7,8-12). The cause of these is not clear. The current 
hypotheses include micro-injuries to the myocardium 
that remain undetected by conventional cardiac imaging, 
cardiotoxicity due to changes in osmolarity and/or ion 
fluxes, increased cardiac preload and myocardial stretch 
due to volume overload and non-ischaemic cardiac injury 
due to calcium and oxalate deposition in the heart (8). 
Other reasons for raised cTnI are the analytical 
interferences that affect almost all cTnI immuno-assays. 
The most frequently described interfering mechanisms 
are those caused by heterophilic antibodies, human anti-
mouse antibodies, rheumatoid factor, macromolecular 
complex, circulating cTnI auto-antibodies and incomplete 
serum separation (7,12). One of the strategies used to 
diminish these interferences is the addition of heterophilic-
antibody-blocking reagent (HBR). This method has 
been used successfully in populations other than those 
of patients with kidney failure, but not in haemodialysis 
patients (12). 
The findings reported here also show the presence of 
false positive and negative results and do not demonstrate 
statistically significant differences between the samples with 
and without added HBR or between plasma and serum. 
This probably means that the nonspecific results found 
are not the consequence of a high titre of heterophilic 
antibodies but rather of some other type of interference, 
or that the blocking reagent HBR does not work on this 
population of patients. However, in accordance with the 
views of other authors, they do allow the recommendation 
of plasma as the sample of choice for cTnI quantification 
in haemodialysis patients. 
The American College of Cardiology (ACC)/American 
Heart Association (AHA) guidelines recommend that 
laboratories should provide cardiac biomarker results 
within 30 to 60 minutes, and the US National Academy 
of Clinical Biochemistry recommends bedside or point-
of care testing if laboratories cannot provide cardiac 
biomarker results consistently within one hour (13). 
For this reason, rapid bedside cTnI assays have been 
successfully trialled on patients with acute coronary 
syndrome, but they have not been extended to those with 
ESRD. The only study so far published concludes that the 
fast tests are less specific than quantitative tests for the 
detection of acute and chronic cardiac manifestations in 
patients with terminal renal failure (14). 
The results of the work being reported here agree with 
that study, since whether or not they had a documented 
cardiac pathology, none of the patients showed positive 
with the Hexagon Troponin test. However, in a parallel 
study it was observed that the same method was specific 
for the diagnosis of acute myocardial infarction and 
unstable angina. On this basis, it is possible to suggest 
that the Hexagon Troponin test is suitable for acute 
myocardial injury, but its use is limited in chronic cardiac 
pathologies like uraemic cardiomyopathy. Nevertheless, 
further research with a larger number of patients would 
be advisable, so as to confirm these findings.
Although over the last 10 years increases in cTnI have 
been observed in ESRD patients (8,15-17), the controversy 
surrounding their specificity and the association between 
troponin I and mortality from all causes is not unfounded, 
and the available evidence does not clarify this association. 
The present study offers various pieces of data that may 
contribute in elucidating this situation. First, raised cTnI, 
as defined by the reference limit for normal subjects, 
was associated with an eight-fold greater risk of death. 
These findings are consistent with previous studies that 
associate high concentrations of cTnI with a greater risk 
of mortality and suggest that the relative risk of death 
varies in accordance with the cut-off point used in each 
study (1-3,15,18). Second, the difference in cTnI levels 
between patients having spent longer and shorter times 
on dialysis permits consideration of the possibility that 
haemodialysis itself could induce myocardial ischaemia 
and a minor degree of troponin I release in patients 
undergoing haemodialysis treatment. This hypothesis is 
also supported by other investigators (18). 
With respect to the specificity of cTnI, some 
studies demonstrate that cTnI is highly specific in this 
type of patients (1,2,18,19) whereas others do not 
acknowledge this (8,9,17). In the current research, a 
significant association was demonstrated between cTnI 
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concentrations and the presence or absence of cardiac 
disease. These data suggest that cTnI levels can serve as 
a useful marker of myocardial injury in patients with 
ESRD on haemodialysis. However, the limited number 
of patients did not allow measurement of the specificity 
and sensitivity of this test. Finally, although a few 
studies exist that evaluate short- and long-term survival 
in haemodialysis patients (8,9,20), the percentage of 
survivors in the present study points to the possibility of 
using undetectable cTnI concentrations as a predictor of 
survival in this population.
In conclusion, the findings suggest that increases in 
circulating cTnI in stable asymptomatic haemodialysis 
patients are associated with a greater risk of death. 
Nevertheless, precision always must be considered within a 
suitable clinical context, and the variables derived from the 
quantification method used require proper evaluation.
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